COVID-19. COVID-19 has been confirmed by laboratory testing irrespective of severity of clinical signs or symptoms
Conditions
Interventions
Intervention 1: Intervention group: Patients in the intervention group, in addition to standard medication (serum therapy, analgesics, antipyretic, and vitamine), take oral Favipiravir at a dose of 16
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: Laboratory covfirmation of COVID-19 virus by RT-PCR or imaging findings consistent with COVID-19 Moderate-severity disease (respiratory rate 94% or pulmonaru infiltration < 50% in both lungs) Age above 14 years Willingness to participate in this study
Exclusion criteria
Exclusion criteria: Immunocompromised patients Pregnancy Consumption of effective drugs in the treatment of COVID-19 in this clinical course History of severe hypersensitivity or anaphylactic shock
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body temperature. Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Thermometer.;Respiratory rate (per minute). Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Physical examination by physician.;Oxygen saturation. Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Pulseoxymeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization. Timepoint: Seventh day from the beginning of treatment. Method of measurement: Patient medical record.;Serum CRP level. Timepoint: Days 1 (start of treatment), 3, 5, and 7. Method of measurement: Laboratory report.;Lymphocyte count. Timepoint: Days 1 (start of treatment), 3, 5, and 7. Method of measurement: Laboratory report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfshin Bagherzade
Shahid Beheshti University of Medical Sciences
Outcome results
None listed